http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Heomatopoietic cell transplantation for malignant conditions
Get a quick, expert overview of hematologic and non-hematologic malignancies for which hematopoietic cell transplantation is a treatment option. Drs. Qaiser Bashir and Mehdi Hamadani provide easy-to-find information on basic science of hematopoietic cell transplantation, pharmacology, workflows and procedures, possible complications and side effects, in addition to the role of HCT in conjunction with clinical cellular therapy. Discusses high-dose chemotherapeutic regimens and radiation therapy, patient and donor selection and workup, as well as other key aspects of hematopoietic cell transplantation. Includes practical information on complications, infectious disease, and special populations such as patients with HIV infection. Consolidates today's available information in this fast-changing area into one convenient resource.
Front Cover; Hematopoietic Cell Transplantation for Malignant Conditions; Hematopoietic Cell Transplantation for Malignant Conditions; Copyright; List of Contributors; Contents; I -- HISTORY AND BASIC SCIENCE OF HEMATOPOIETIC CELL TRANSPLANTATION; 1 -- History and Current Status of Hematopoietic Cell Transplantation; INTRODUCTION; BMT Developments in 1950s to Early 1960s; The Significance of HLA Matching in Transplant; Late 1960s: The First Successful HLA-Matched Sibling BMTs; Late 1970s to Mid-1980s: Use of Unrelated Donors; 1980−90: Use of PB as Autograft
Early 1990s: Rapid Increase in Allogeneic Transplantation Using PB GraftsHaploidentical Stem Cell Transplantation; History of Umbilical Cord Blood Transplant; Late 1990s to Early 2000s: Introduction of RIC; Origin of Donor and Transplant Registries; CONCLUSION; REFERENCES; II -- HEMATOPOIETIC CELL TRANSPLANTATION PHARMACOLOGY; 2 -- Pharmacology of Drugs Used in Hematopoietic Cell Transplantation; INTRODUCTION; IMMUNOSUPPRESSANTS; Cyclosporine; Pearls; Tacrolimus; Pearls; Methotrexate; Mycophenolate; Sirolimus; Pearls; Cyclophosphamide; Antithymocyte Globulin; Pearls; Alemtuzumab; Pearls
CorticosteroidsPearls; ANTIMICROBIAL AGENTS; Trimethoprim/Sulfamethoxazole; Piperacillin/Tazobactam; Pearl; Cephalosporins; Carbapenems; Vancomycin; Pearl; Metronidazole; Antivirals; Antifungals; ANTIDIARRHEAL AGENTS; Loperamide; Diphenoxylate and Atropine; Octreotide; MISCELLANEOUS; Defibrotide; Ursodiol; Deferasirox; Intravenous Immune Globulin; Palifermin; REFERENCES; 3 -- High-Dose Chemotherapy Regimens; GOALS OF CONDITIONING REGIMENS; TYPES OF CONDITIONING REGIMENS; NONCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS; Total-Body Irradiation; Radioisotopes and Radioimmunotherapy
90Y-Ibritumomab TiuxetanCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS; ALKYLATING AGENTS; Busulfan; Cyclophosphamide; Ifosfamide; Melphalan; Thiotepa; Carmustine; Bendamustine; ANTIMETABOLITES; Fludarabine; Clofarabine; Cytarabine; Gemcitabine; PLATINUM AGENTS; Carboplatin; PLANT ALKALOIDS; Etoposide; ANTI-T CELL ANTIBODIES; MONOCLONAL ANTIBODIES; Rituximab; DOSING CONSIDERATIONS; Organ Dysfunction; Renal; Hepatic; Dosing Principles; Dosing in Obese Patients; REFERENCES; 4 -- The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation; TOTAL-BODY IRRADIATION THERAPY
Myeloablative Conditioning RegimensReduced-Intensity Conditioning Regimens; CNS Leukemic Involvement; Toxicity after HSCT: contributions from TBI; THE ROLE OF RT AMONG PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA UNDERGOING HSCT; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Toxicity Among HL and NHL Patients; CONCLUSIONS; DISCLOSURE STATEMENT; REFERENCES; III -- WORKFLOWS AND PROCEDURES IN HEMATOPOIETIC CELL TRANSPLANTATION; 5 -- Sources of Cells for Hematopoietic Cell Transplantation: Practical Aspects of Hematopoietic Cell Collection; INTRODUCTION
edited by Qiaser Bashir, Mehdi Hamadani.
SOURCES OF CELLS FOR ALLOGENEIC TRANSPLANTATION